EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Tag

rivoceranib

Elevar Announces Results from the Angel Trial, A Study of Monotherapy Rivoceranib (Apatinib) In Late-Stage Gastric Cancer Patients

At ESMO 2019, Elevar Therapeutics announced that in a phase 3 trial in gastric cancer patients, rivoceranib did not improve overall survival...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

18 hours ago

The International Agency for Research on Cancer, WHO estimates there will be 15.6 million cases of gastric cancer diagnosed worldwide in people born between 2008 and 2017, 76% of which will be linked to H. pylori infection. The authors argue for increased investment in preventative strategies. Via Nature Medicine ... See MoreSee Less

Global lifetime estimates of expected and preventable gastric cancers across 185 countries - Nature Medicine

www.nature.com

Global estimates of expected and preventable gastric cancers in people born between 2008 and 2017 report that there will be 15.6 million lifetime gastric cancer cases, three-quarters of which are prev...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 days ago

Why quitting smoking significantly decreases the risk of gastric cancer, via OncoDaily: ... See MoreSee Less

Gastric Cancer and Smoking — What Are the Shocking Real Risks? - OncoDaily

oncodaily.com

Gastric cancer and smoking , tobacco use significantly increasing the likelihood of developing this disease.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

Recent data showing positive results from a trial combining durvalumab (Imfinzi) with FLOT chemotherapy will be “practice changing,” said Gastric Cancer Foundation grantee Samuel Klempner of Massachusetts General Hospital. Via Targeted Oncology ... See MoreSee Less

Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer

www.targetedonc.com

Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant therapy according to the MATTERHORN trial.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Amgen ’s experimental gastric cancer drug bemarituzumab, which targets FGFR2b overexpression, improved overall survival when combined with chemotherapy in a phase 3 clinical trial. ... See MoreSee Less

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER| Amgen

www.amgen.com

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

In a comprehensive review, researchers at Chinese University of Hong Kong identified several risk factors for gastric cancer, including two stomach microbes, Streptococcus anginosus and Fusobacterium nucleatum. ... See MoreSee Less

New insights into the role of diet and microbiome in gastric cancer

www.news-medical.net

Gastric cancer (GC), once primarily seen in older adults, is on the rise among younger individuals in developed countries.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X